Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
F275360-25mg | 25mg | In stock | $17.90 | |
F275360-100mg | 100mg | In stock | $58.90 | |
F275360-500mg | 500mg | In stock | $265.90 |
γ-secretase inhibitor
Synonyms | Tarenflurbil|51543-40-9|Flurizan|(R)-Flurbiprofen|R-Flurbiprofen|(R)-2-Flurbiprofen|(R)-2-Flubiprofen|MPC-7869|(R)-2-(2-Fluoro-[1,1'-biphenyl]-4-yl)propanoic acid|(2R)-2-(3-fluoro-4-phenylphenyl)propanoic acid|Flurbiprofen, (r)-|(2r)-2-(3-Fluoro-4-Phenyl- |
---|---|
Specifications & Purity | ≥99% |
Storage Temp | Store at -20°C,Argon charged |
Shipped In | Dry ice |
Action Type | MODULATOR |
Mechanism of action | Gamma-secretase modulator |
Product Description | Tarenflurbil ((R)-Flurbiprofen) is the R-enantiomer of the racemate NSAID Flurbiprofen, Tarenflurbil ((R)-Flurbiprofen) inhibits the binding of [3H]9-cis-RA to RXRα LBD with IC50 of 75 μM. Tarenflurbil can be used for Alzheimer's disease research. |
ALogP | 4.2 |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Pubchem Sid | 488186703 |
---|---|
Pubchem Sid Url | https://pubchem.ncbi.nlm.nih.gov/substance/488186703 |
IUPAC Name | (2R)-2-(3-fluoro-4-phenylphenyl)propanoic acid |
INCHI | InChI=1S/C15H13FO2/c1-10(15(17)18)12-7-8-13(14(16)9-12)11-5-3-2-4-6-11/h2-10H,1H3,(H,17,18)/t10-/m1/s1 |
InChi Key | SYTBZMRGLBWNTM-SNVBAGLBSA-N |
Canonical SMILES | CC(C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)O |
Isomeric SMILES | C[C@H](C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)O |
PubChem CID | 92337 |
Molecular Weight | 244.26 |
PubChem CID | 92337 |
---|---|
Wikipedia | Tarenflurbil |
CAS Registry No. | 51543-40-9 |
ChEMBL Ligand | CHEMBL190083 |
ChEBI | CHEBI:38666 |
DrugBank Ligand | DB05289 |
RCSB PDB Ligand | FLR |
PubChem SID | 488186703 |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
E2317614 | Certificate of Analysis | Mar 22, 2024 | F275360 |
E2317651 | Certificate of Analysis | Mar 22, 2024 | F275360 |
E2317667 | Certificate of Analysis | Mar 22, 2024 | F275360 |
E2317615 | Certificate of Analysis | Mar 07, 2024 | F275360 |
E2317613 | Certificate of Analysis | Mar 07, 2024 | F275360 |
E2317612 | Certificate of Analysis | Mar 07, 2024 | F275360 |
Solubility | Soluble in ethanol to 100 mM and in DMSO to 25 mM |
---|
Pictogram(s) | GHS06 |
---|---|
Signal | Danger |
Hazard Statements | H301:Toxic if swallowed |
Precautionary Statements | P321:Specific treatment (see ... on this label). P405:Store locked up. P501:Dispose of contents/container to ... P264:Wash hands [and …] thoroughly after handling. P270:Do not eat, drink or smoke when using this product. P330:Rinse mouth. P301+P316:IF SWALLOWED: Get emergency medical help immediately. |
1. Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH, Tarenflurbil Phase 3 Study Group. (2009) Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.. JAMA, 302 (23): (2557-64). [PMID:20009055] |
2. Xia W, Wong ST, Hanlon E, Morin P. (2012) γ-Secretase modulator in Alzheimer's disease: shifting the end.. J Alzheimers Dis, 31 (4): (685-96). [PMID:22710916] |